Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer
NCT02674568
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
342
Enrollment
INDUSTRY
Sponsor class
Conditions
Small Cell Lung Cancer
Interventions
DRUG:
Rovalpituzumab tesirine
Sponsor
AbbVie